Intensity Therapeutics, Inc.
INTS
Rank in Stocks
#29234
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$8.51M
Change (1 day)
5.00%
Change (1 year)
-67.69%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Intensity Therapeutics, Inc. (INTS)
Category
Healthcare
Earnings for Intensity Therapeutics, Inc. (INTS)
Earnings in Sep 2026 TTM: $-12.04M
According to Intensity Therapeutics, Inc.'s latest financial reports, its current earnings (TTM) are $-12.04M. In 2025 the company earned $-11.61M, an increase over its 2024 earnings of $-16.27M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Intensity Therapeutics, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-12.04M | 3.70% |
| 2025 | $-11.61M | -28.66% |
| 2024 | $-16.27M | 54.37% |
| 2023 | $-10.54M | 38.99% |
| 2022 | $-7.58M | -3.97% |
| 2021 | $-7.90M | 30.92% |
| 2020 | $-6.03M | 12.09% |
| 2019 | $-5.38M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -39,643.87% |
US
|
|
| $-2.73B | 22,573.65% |
US
|
|
| $-4.02B | 33,268.20% |
AU
|
|
| $2.83B | -23,578.09% |
BE
|
|
| $1.50B | -12,537.21% |
NL
|
Questions about Intensity Therapeutics, Inc.'s net income
What is Intensity Therapeutics, Inc.'s net income?
Intensity Therapeutics, Inc.'s net income over the last twelve months is $-12.04M, as of Sep 2026.
What was Intensity Therapeutics, Inc.'s net income in 2025?
In 2025, Intensity Therapeutics, Inc.'s net income was $-11.61M, compared with $-16.27M in 2024.
How has Intensity Therapeutics, Inc.'s net income changed since 2020?
From 2020 to 2025, Intensity Therapeutics, Inc.'s net income was highest in 2020 ($-6.03M) and lowest in 2024 ($-16.27M).
How does Intensity Therapeutics, Inc.'s net income compare with similar companies?
Intensity Therapeutics, Inc.'s net income ($-12.04M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.